(MENAFN- ProactiveInvestors)Pre-revenue diabetes and obesity specialist M Pharmaceutical's (CNSX:MQ OTCMKTS:MPHMF) third quarter results showed the signs of the company's vigorous transformation. It is less than a year since the former First Sahara Energy changed tack to focus on the pharmaceutical and biomedical device markets with a particular onus on tackling diabetes obesity and other gastroenterological indications and the company certainly has not let the grass grow under its feet signing a succession of deals. The need to do all that due diligence is reflected in consulting fees in the third quarter which rose to C$434590 from C$107789 the year before which was a major factor in the loss before exceptional items widening to C$599731 from C$205348 a year earlier. The company also took a paper-based loss of C$132307 on a change in the fair value of its investments.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.